Kornimate/medical-research-clean huggingface dataset:
an randomized control trial comparing two drug combinations for pain management after third molars surgery

Conditions: Impacted Third Molar Tooth; PAIN

Summary: randomised control clinical trial to compare which combination of analgesics in effective in pain management after third molar extraction of wisdom teeth. the study will assess post operative pain after third molar extraction of two groups of study participants who will be given one of the two combinations of diclofenac/ acetaminophen/codeine and ibuprofen/acetaminophen/codeine .

double blind randomized control clinical trial to compare the level of pain relief that occurs after third molar extraction done under local anaesthesia at the maxillofacial center, harare, zimbabwe. the participants will be randomized into two arms upon fitting the inclusion criteria.the pharmacist will be in charge of randomization and will randomise the participants upon giving them the medications. one group will receive combination of diclofenac/acetaminophen/codeine and the other group will receive ibuprofen/acetaminophen/codeine as post extraction analgesia.the dosages of the medications will be diclofenac 50mg, ibuprofen 400mg, acetaminophen 500mg and codeine 15mg respectively. questionnaires will be given to the patient to complete after discharge from the surgery and other parts of the questionnaire will be completed on review after 7 days. a record will be done of the postoperative pain experience (using visual analogue scale), use of rescue medication and details pertaining to impacted tooth.

Eligibility criteria:
inclusion criteria: * patients older than 18 years of age * patients undergoing third molar extractions * patients with or willing to get orthopantomogram for assessment of impacted third molars exclusion criteria: * patients younger than 18 years * patients not willing to consent to the study * patients with associated co-morbidities * patients not willing to undergo radiological evaluation * patients allergic to medications used in the study * pregnant patients
early detection of burnout - healthcare workers

Conditions: Healthcare Workers; Stress; Occupation

Summary: burnout is a public health issue. healthcare workers are particularly at risk of burnout with occupational stress identified as the major risk factor. the "health work environment" service is composed of physicians, nurses and psychologist with the aim of providing efficient and adapted care for healthcare workers at chu of clermont-ferrand. in addition, they must ensure a role of primary, secondary and tertiary prevention. with regard to burnout, the majority of the work carried out concerns tertiary prevention, that is to say the care of a person in a situation of burnout. it would be necessary to carry out secondary prevention in order that people at risk of burnout can be detected earlier. however, there is currently no individual questionnaire to detect early burnout

early detection of burnout was designed to provide a better understanding of warning sign of burnout in order to detect earlier workers at risk. in the present protocol, parameters are measured on several occasions (0, 1 week, at 6 month, at 12 months and then at each occupational visit within 5 years). statistical analysis will be performed using stata software (version 13; stata-corp, college station, tex., usa). all statistical tests will be two-sided and p\<0.05 will be considered significant. after testing for normal distribution (shapiro-wilk test), data will be treated either by parametric or non-parametric analyses according to statistical assumptions. inter-groups comparisons will systematically be performed 1) without adjustment and 2) adjusting on factors liable to be biased between groups. analysis will be performed using anova or kruskal-wallis (kw) tests. when appropriate (p\<0.05), a post-hoc test for multiple comparisons (tukey-kramer after anova and dunn post kw) will be used. comparisions of categorical variables will be performed using chi-squared or fischer test. marascuillo's procedure will be performed for multiple comparisons. relations between quantitative outcomes will be analyzed using correlation coefficients (pearson or spearman). fisher's z transformation and william's t2 statistic will be performed to compare correlations between variables and within a single group of subjects. longitudinal data will be treated using mixt-model analyses in order to treat fixed effects group, time and group x time interaction taking into account between and within participant variability.

Eligibility criteria:
inclusion criteria: * healthcare workers at clermont-ferrand hospital * aged: from 18 years to retirement exclusion criteria: * participant refusal to participate * no healthcare workers at clermont-ferrand hospital
validation of in vitro method for anti-mcpyv immunotherapy on patients with cutaneous merkel cell carcinoma

Conditions: Merkel Cell Carcinoma of Skin

Summary: the aim of the study is to test and validate in vitro a cell therapy approach for mcpyv+ merkel cell carcinoma patients.

the aim of the study is to test and validate in vitro a cell therapy approach for mcpyv+ merkel cell carcinoma patients.

Eligibility criteria:
inclusion criteria: * patients \>= 18 years old; * diagnosed with merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up; * informed for the study and no-opposed for participation; * affiliated with a social security scheme or in an equivalent situation. exclusion criteria: * patients ongoing another interventional clinical trial; * patients under guardianship or trusteeship; * pregnancy or breastfeed; * patients refusal.

Keywords: merkel cell carcinoma of skin
mc5-a scrambler therapy for the treatment of chronic neuropathic extremity pain

Conditions: Peripheral Neuropathy; Low Back Pain

Summary: the fda-approved mc5-a scrambler therapy (mc5-a st) is an electroanalgesia device that interferes with pain signal transmission by using nerve fibers as a passive means to convey a message of normality (sans pain) to the central nervous system. while preliminary research has demonstrated its efficacy in treating chronic neuropathic pain secondary to cancer and failed back surgery syndrome, its effectiveness in treating chronic neuropathic pain secondary to traumatic musculoskeletal injuries like those experienced in combat has not been investigated. the purpose of this prospective, double-blind, randomized controlled, study is to determine if the mc5-a st is efficacious in altering the biological, psychological, and social components of the chronic neuropathic pain experience in military service members (sms) with traumatic musculoskeletal extremity injuries.


Eligibility criteria:
inclusion criteria: * military service members (active duty \& retirees) between the ages of 18 and 79, inclusive * neuropathic pain symptoms present for 3 months or greater prior to entry into the study * rated pain intensity equal to or greater than 3 on nrs-11 pain scale * painful peripheral neuropathy in an extremity that is the result of a traumatic injury (post-traumatic/ post-surgical neuropathy, stump pain, entrapment neuropathy), or low back pain with radiculopathy * stable pain medication treatment regimen * able to speak and read english, understand the study procedures, and consent to study participation exclusion criteria: * pacemaker or other implantable devices * vena cava, aneurysm clips, coronary or other vascular stents * pregnancy via a pregnancy test * history of epilepsy, brain injury, symptomatic brain metastases * prior celiac plexus block, or other neurolytic pain control treatment, within 4 weeks * wounds or skin irritation in areas where the electrodes are required to be placed * cardiac ischemia within the previous 6 months * severe arrhythmia * documented history of moderate or severe traumatic brain injury * latex allergies * open wound over site of chronic pain * unable to stop anti-epileptic medications or gabapentin over 2 weeks of mc5-a st treatment * history of electroanalgesia treatment (electroacupuncture, biomodulator, tens) over last 30 days * participation in the study would delay the medical board (meb) processing of the service member off of active duty status or would delay a return to duty status to their home unit. * metal implants such as cardiac pacemakers, automatic defibrillators, aneurysm clips, vena cava clips and skull plates

Keywords: peripheral neuropathy traumatic tissue injury radiculopathy
an efficacy study of combination of tramadol and acetaminophen tablets in the treatment of participants with fibromyalgia pain

Conditions: Pain; Fibromyalgia

Summary: the purpose of this study is to evaluate the analgesic effect of combination of tramadol hydrochloride and acetaminophen in participants for treatment of fibromyalgia pain (chronic widespread pain and presence of tender points).

this is an open-label (all people know the identity of the intervention) and multi-center (conducted in more than one center) study of combination of tramadol hydrochloride and acetaminophen in treatment of participants with pain of fibromyalgia. the duration of this study will be 56 days per participant. the study consists of 2 parts: screening (that is, 3 weeks before study commences on day 1) and treatment (that is, up to day 56). all the eligible participants will receive oral tablet for combination of tramadol hydrochloride and acetaminophen. rescue medication (a medication intended to relieve symptoms immediately) of tylenol (500 milligram, up to 6 oral tablets daily) will be permitted throughout the study duration. efficacy of the participants will primarily be evaluated by pain visual analog scale. participants' safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * participants must meet the american college of rheumatology 1990 criteria for the classification of fibromyalgia (that are, participants must have had widespread pain \[pain in three quadrants and in the axial skeleton\] for at least three months and pain on digital palpation in 11 or more of the 18 tender-point sites * female participants must not be pregnant, breast feeding or postmenopausal for at least one year * participant must be able to take oral medication * participants must have completed the screening or wash-out procedures and have a visual analog scale score greater than or equal to 40 milliliter * fail to non-opioid analgesics exclusion criteria: * participants who previously failed tramadol hydrochloride therapy or those who discontinued tramadol hydrochloride due to adverse events * participants diagnosed with either any active connective tissue or musculo-skeletal diseases, or malignancy or history of malignancy within past 5 years, or painful, symptomatic osteoarthritis, or regional periarticular pain syndromes, spondyloarthropathy and major endocrine disease * participants who currently have more severe pain than the pain of fibromyalgia * participants who have taken antidepressants, cyclobenzaprine or anti-epileptic drugs for pain within three weeks of the treatment phase * participants who have taken short-acting analgesics, topical medications and anesthetics and/or muscle relaxants for a period of less than 21 days of the given medication prior to the treatment phase

Keywords: pain fibromyalgia ultracet tramadol hydrochloride acetaminophen
clinical study of mrna vaccine in patients with advanced malignant solid tumors

Conditions: Advanced Malignant Solid Tumors

Summary: this study is an open, single arm, dose increasing study to evaluate the safety and efficacy of the combination of mrna personalized tumor vaccine encoding neoantigen (hereinafter referred to as tumor vaccine) and sintilimab injection (hereinafter referred to as sintilimab) in the treatment of advanced malignant solid tumors.


Eligibility criteria:
inclusion criteria: * are ≥18 years old, without limitation of sex at time of consent. * patients with malignant solid tumors confirmed by histopathology or cytology and having at least one measurable lesion. * fresh biopsy specimens can be provided for vaccine preparation. * patients with malignant solid tumors who develop secondary drug resistance after receiving pd-1/pd-l1 drug therapy, including but not limited to gastric cancer, esophageal cancer, and other gastrointestinal tumors of msi-h exclusion criteria: * it is known that it is allergic to any tumor vaccine and sintilimab preparations; or have experienced severe allergic reactions to other monoclonal antibodies in the past; * the predicted number of new antigens is less than 10; * those who are pregnant or breastfeeding; * those with an expected survival period of less than 3 months;
effects of modified otago versus action observation on strength, mobility and fall risk in diabetic neuropathy

Conditions: Diabetic Neuropathies; Mobility; Fall

Summary: to compare the effects of modified otago exercise and action observation training on strength, functional mobility and fall risk in patients with diabetic neuropathy.

this study will be a randomized clinical trial. a total of 38 participants with diabetic neuropathy will be taken. by using non probability convenience sampling technique patients will be randomized and allocated into two intervention groups based on inclusion and exclusion criteria.patients in group a will receive modified otago exercises with conventional treatment.patients in group b will receive action observation training with conventional treatment.all participants will receive treatment of 40 minutes per session for 5 days a week for 8 weeks.the michigan neuropathy screening instrument will be used for the assessment of diabetic neuropathy score.the strength,functional mobility and fall risk will be assessed by using 30 second chair stand test, timed up and go test and fall efficacy scale.

Eligibility criteria:
inclusion criteria: * individuals with type 2 diabetes already diagnosed by physician from last 2 years * able to take instructions exclusion criteria: * additional neurological problem guillain barre syndrome, parkinson disease, multiple sclerosis, other than neuropathy * participant with visual, vestibular system and auditory problems * participant with cardiovascular problem, cerebrovascular problem and epilepsy

Keywords: diabetic neuropathies mobility fall
sacral neuromodulation as treatment for fecal incontinence

Conditions: Fecal Incontinence

Summary: the objective of this study is to investigate if low level laser therapy will do more good than harm for patients with severe refractory fecal incontinence. it is a proof of concept study without a placebo arm.

the therapy consists of a 3 week treatment with a total of 8 sessions of low level laser therapy. effects will be assessed using symptoms and quality of life questionnaires and physiological assessments of pelvic floor function, at 4 weeks and 12 weeks after beginning of treatment.

Eligibility criteria:
inclusion criteria: patients with fecal incontinence exclusion criteria: * pregnant patients * known malignancies in the area of treatment * active bleeding in area of treatment * active deep vein thrombosis * when tatoos are present at area of treatment * patients that are light sensitive * patients who take steroids.

Keywords: fecal incontinence anorectal manometry
staccato loxapine pulmonary safety in patients with asthma

Conditions: Asthma

Summary: the purpose of this study is to assess the safety of 2 inhaled doses of staccato loxapine within a day in patients with asthma.


Eligibility criteria:
inclusion criteria: * history of mild to moderate persistent asthma for at least 6 months with pre-bronchodilator fev1 ≥60% of predicted value. exclusion criteria: * history of copd, or any other acute or chronic pulmonary disease

Keywords: asthma, staccato loxapine
the effects of using virtual reality glasses during the non-stress test

Conditions: Pregnancy Related

Summary: the aim of this study to determine the effect of virtual reality glasses use on anxiety, stress and fetal well-being during the non-stress test. personal information form was used as data collection form, revised prenatal distress questionnaire (nupdq-17 item version) was used to assess distress, state-trait anxiety inventory (stai) was used to assessanxiety.

material and method this research was conducted between between october 2021 and february 2022 in fethi sekin city hospital. when power analysis was performed, the sample size was calculated to be at least 71 women for each group (71 experiments, 71 controls). during the nst procedures, vr glasses were given to the participants in the experimental group by the researcher for the intervention. data collection form for experimental and control groups before the nst procedures; revised prenatal distress questionnaire (nupdq-17 item version) and state-trait anxiety inventory (stai) were applied two times before and after nst procedure. after the nst procedures, both groups were re-administered. descriptive statistics and independent t-test were used for data analysis.

Eligibility criteria:
inclusion criteria: * not carrying any risk factors (e.g., preeclampsia, intrauterine growth retardation (iugr), premature rupture of membranes, gestational diabetes) * having a singleton pregnancy and no vision problems * no uterine contraction on the tracing paper at the end of nst * having eaten at least two hours before nst * not smoking or drinking alcoholic beverages at least two hours before nst * having a systolic blood pressure value in the range of 90-140 mmhg and a diastolic blood pressure value in the range of 60-90 mm/hg * not having any problems related to the health of the fetus (such as fetal anomaly, intrauterine growth retardation) * having no communication barriers. exclusion criteria: * presence of fetal distress and emergency intervention planned by the physician * uterine contraction as a result of nst

Keywords: anxiety non-stress test stress virtual glasses
determine safety and efficacy of long-term oral lacosamide in patients with partial seizures

Conditions: Partial Epilepsies

Summary: the purpose of this trial is to determine whether lacosamide is safe and effective for long-term use in patients with partial-seizures from epilepsy


Eligibility criteria:
inclusion criteria: * completion of parent clinical trial for treatment of partial seizures exclusion criteria: * receiving any study drug or experimental device other than lacosamide * meets withdrawal criteria for parent trial or experiencing ongoing serious adverse event

Keywords: adjunctive treatment in epilepsy add-on treatment for epilepsy partial seizures aeds antiepileptic drugs seizures
resting energy expenditure equations in amyotrophic lateral sclerosis, creation of a als-specific equation

Conditions: Amyotrophic Lateral Sclerosis

Summary: introduction: resting energy expenditure (ree) formulas for healthy people (hp) are used to calculate ree (cree) in amyotrophic lateral sclerosis (als) patients. in als an increase of measured ree (mree) in indirect calometry (ic) compared to cree is found in 50-60%. the aims were (i) to assess accuracy of cree assessed using eleven formulas as compared to mree and (ii) to create if needed a specific cree formula for als patients. method: als patients followed in the als expert center of limoges between 1996 and 2014 and with a nutritional evaluation were included. mree assessed with ic and cree calculated with eleven predictive formulas (harris benedict (hb) 1919, hb 1984, wschofield, de lorenzo, johnstone, mifflin, who/fao, owen, fleisch, wang and rosenbaum) were collected at time of diagnosis. fat free mass (ffm) and fat mass (fm) were measured with impedancemetry. a bland and altman analysis was carried out. the percentage of accurate prediction ± 10%of mree, and intraclass correlation coefficients (icc) were calculated. using a derivation sample, a new ree formula was created using multiple linear regression according to sex, age, ffm and fm. accuracy of this formula was assessed in a validation sample.


Eligibility criteria:
inclusion criteria: * als diagnosed patients according to airlie house criteria * treated with riluzole * respiratory quotient (rq) of patients in indirect calorimetry (ic) should be in between 0.7 and 0.87 exclusion criteria: -
malabsorption blood test:toward a novel approach to quantify steatorrhea

Conditions: Cystic Fibrosis; Pancreatic Insufficiency

Summary: \*the purpose of this study is to develop a more accurate, reliable, specific and more acceptable alternative clinical test to the 72-hour stool and diet collection for quantifying fat malabsorption in people with cf and pancreatic insufficiency.

* nine subjects with cf will be recruited to complete the mbt on two separate occasions, with different doses of pancreatic enzymes * at each mbt visit, subjects will receive a specific enzyme dose just before they drink the test meal (shake) * fat absorption is maximized when the enzymes are taken with the shake. * if subjects usually receive brands of pancreatic enzymes different from creon, their dose will be converted to an equivalent dose of creon 20 for the study. prior to each study visit all subjects will be required to: * eat their usual diet for 2 days prior to mbt * refrain from consuming alcohol or dairy products for 24 hours prior to mbt * refrain from non-routine physical exercise for 20 hours prior to mbt * adhere to a 12-hour fast prior to mbt (from 8 pm previous night) * can drink water from 8:00 pm on the night before the test to 2:00 am on the day of the test * at visits 1 and 2, blood samples will be obtained at hourly intervals over a period of eight hours. * samples will be analyzed for pa, ha and triglyceride concentrations. * patients will be permitted to ingest non-caloric and non-caffeinated beverages. * at hour 6, patients will be provided 1000 kcal, low fat (12 grams of fat) lunch meal.

Eligibility criteria:
inclusion criteria: * subjects with cystic fibrosis and pancreatic insufficiency (n=9), 8 years of age or older, in usual state of good health will be eligible to participate in this aim. * subjects will be screened for genotype and a history of pancreatic insufficiency (pi). pi will be confirmed by measurement of fecal elastase 1\< 200 mg/g stool. exclusion criteria: * subjects will be ineligible if they have an fev1 % predicted of \ 10 cm) with the exception of a routine, uncomplicated appendectomy. * subjects with diabetes mellitus or disorders associated with altered energy metabolism (i.e. hypothyroidism), or any major illnesses that affect the gastrointestinal tract, will not be eligible for the study. * subjects with significant liver disease, or significant developmental delay will also be excluded. * subjects will be excluded if they have a food allergy related to any components of the experimental shake (i.e., soy or chocolate) or the stool marker, carmine red. * subjects who are pregnant are not eligible. subjects with a history of intolerance or allergy to creon 20 will be excluded from the study.

Keywords: new diagnostic test for cystic fibrosis.